Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey

In Turkey, non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in men and one of the most common causes of cancer-related deaths in women. Because of the heterogeneity of NSCLC or SCLC, it is crucial to characterize the biology of the tumor as exact as possible, to predict the course of disease as accurate as possible, and to determine the optimal therapeutic algorithm as early as possible after initial diagnostic work-up.

These efforts are an obligatory part of the initial diagnostics, since thorough knowledge of the biology of the disease and the resulting therapeutic options ensure optimal care of Volunteers with NSCLC or SCLC. The aim of REGISTURK is to set up a national clinical research platform to document molecular testing, treatment and course of disease of patients with NSCLC or SCLC.

Inclusion Criteria:

1. Patient histopathologically diagnosed with non-small cell lung cancer or small cell lung cancer
2. Written informed consent no later than six weeks after start of first-line treatment
3. Age ≥ 18 years

Exclusion Criteria:

• Volunteers participating in a research program for non-small cell or small cell lung cancer that includes interventions outside of routine clinical trial

Six thousands REGISTURK patients treated at 42 study sites (university hospitals, education and research hospitals and private hospital-based oncology practices).REGISTURK sites will be selected in accordance with patients load, hospital type and geographical distribution. All patients diagnosed with NSCLC or SCLC at selected centers will be enrolled consecutively throughout the study period. All patients diagnosed with lung cancer who receive treatment or who are followed with the best supportive care approach or refuse treatment will be recorded. All approaches in this regard will be determined and the reasons will be examined. Adult male and female patients with non-small cell (early, locally advanced or metastatic) or small cell will be considered "REGISTURK-LUNG patients"